Lawrence Corey (Q139454): Difference between revisions
From geokb
(Created a new Item: Person record added from ORCID registry based on ORCID ID found as author/contributor to USGS publication) |
(Changed an Item: added Wikidata same as link) |
||||||||||||||
(7 intermediate revisions by the same user not shown) | |||||||||||||||
description / en | description / en | ||||||||||||||
USGS collaborator/co-author with Fred Hutchinson Cancer Research Center | |||||||||||||||
Property / instance of: person / reference | |||||||||||||||
Property / ORCID iD: 0000-0002-2179-2436 / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Herpesviruses: Epidemiology, Pathogenesis, and Management / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Herpesviruses: Epidemiology, Pathogenesis, and Management / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Herpesviruses: Epidemiology, Pathogenesis, and Management / qualifier | |||||||||||||||
prevalence: 102
| |||||||||||||||
Property / knows about: Herpesviruses: Epidemiology, Pathogenesis, and Management / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Epidemiology and Management of Cytomegalovirus Infection / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Epidemiology and Management of Cytomegalovirus Infection / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Epidemiology and Management of Cytomegalovirus Infection / qualifier | |||||||||||||||
prevalence: 101
| |||||||||||||||
Property / knows about: Epidemiology and Management of Cytomegalovirus Infection / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome / qualifier | |||||||||||||||
prevalence: 75
| |||||||||||||||
Property / knows about: Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Prevention and Treatment of HIV/AIDS Infection / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Prevention and Treatment of HIV/AIDS Infection / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Prevention and Treatment of HIV/AIDS Infection / qualifier | |||||||||||||||
prevalence: 34
| |||||||||||||||
Property / knows about: Prevention and Treatment of HIV/AIDS Infection / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Parvovirus B19 Infection and Pathogenesis / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Parvovirus B19 Infection and Pathogenesis / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Parvovirus B19 Infection and Pathogenesis / qualifier | |||||||||||||||
prevalence: 32
| |||||||||||||||
Property / knows about: Parvovirus B19 Infection and Pathogenesis / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Natural Killer Cells in Immunity / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Natural Killer Cells in Immunity / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Natural Killer Cells in Immunity / qualifier | |||||||||||||||
prevalence: 31
| |||||||||||||||
Property / knows about: Natural Killer Cells in Immunity / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Efficacy and Safety of Antiretroviral Therapy for HIV / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Efficacy and Safety of Antiretroviral Therapy for HIV / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Efficacy and Safety of Antiretroviral Therapy for HIV / qualifier | |||||||||||||||
prevalence: 30
| |||||||||||||||
Property / knows about: Efficacy and Safety of Antiretroviral Therapy for HIV / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Epidemiology and Pathogenesis of Respiratory Viral Infections / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Epidemiology and Pathogenesis of Respiratory Viral Infections / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Epidemiology and Pathogenesis of Respiratory Viral Infections / qualifier | |||||||||||||||
prevalence: 30
| |||||||||||||||
Property / knows about: Epidemiology and Pathogenesis of Respiratory Viral Infections / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Hepatitis C Infection and Treatment / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Hepatitis C Infection and Treatment / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Hepatitis C Infection and Treatment / qualifier | |||||||||||||||
prevalence: 27
| |||||||||||||||
Property / knows about: Hepatitis C Infection and Treatment / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Gene Therapy Techniques and Applications / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Gene Therapy Techniques and Applications / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Gene Therapy Techniques and Applications / qualifier | |||||||||||||||
prevalence: 27
| |||||||||||||||
Property / knows about: Gene Therapy Techniques and Applications / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Viral-Related Cancers in Immunocompromised Patients / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Viral-Related Cancers in Immunocompromised Patients / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Viral-Related Cancers in Immunocompromised Patients / qualifier | |||||||||||||||
prevalence: 24
| |||||||||||||||
Property / knows about: Viral-Related Cancers in Immunocompromised Patients / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Hepatitis B Infection and Treatment / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Hepatitis B Infection and Treatment / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Hepatitis B Infection and Treatment / qualifier | |||||||||||||||
prevalence: 23
| |||||||||||||||
Property / knows about: Hepatitis B Infection and Treatment / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Coronavirus Disease 2019 Research / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Coronavirus Disease 2019 Research / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Coronavirus Disease 2019 Research / qualifier | |||||||||||||||
prevalence: 20
| |||||||||||||||
Property / knows about: Coronavirus Disease 2019 Research / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Prediction of Peptide-MHC Binding Affinity / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Prediction of Peptide-MHC Binding Affinity / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Prediction of Peptide-MHC Binding Affinity / qualifier | |||||||||||||||
prevalence: 19
| |||||||||||||||
Property / knows about: Prediction of Peptide-MHC Binding Affinity / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Hematopoietic Stem Cell Biology / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Hematopoietic Stem Cell Biology / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Hematopoietic Stem Cell Biology / qualifier | |||||||||||||||
prevalence: 18
| |||||||||||||||
Property / knows about: Hematopoietic Stem Cell Biology / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Immunobiology of Dendritic Cells / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Immunobiology of Dendritic Cells / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Immunobiology of Dendritic Cells / qualifier | |||||||||||||||
prevalence: 17
| |||||||||||||||
Property / knows about: Immunobiology of Dendritic Cells / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Polyomavirus-Associated Carcinogenesis and Clinical Manifestations / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Polyomavirus-Associated Carcinogenesis and Clinical Manifestations / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Polyomavirus-Associated Carcinogenesis and Clinical Manifestations / qualifier | |||||||||||||||
prevalence: 14
| |||||||||||||||
Property / knows about: Polyomavirus-Associated Carcinogenesis and Clinical Manifestations / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Factors Affecting Vaccine Hesitancy and Acceptance / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Factors Affecting Vaccine Hesitancy and Acceptance / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Factors Affecting Vaccine Hesitancy and Acceptance / qualifier | |||||||||||||||
prevalence: 12
| |||||||||||||||
Property / knows about: Factors Affecting Vaccine Hesitancy and Acceptance / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Influenza Virus Research and Epidemiology / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Influenza Virus Research and Epidemiology / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Influenza Virus Research and Epidemiology / qualifier | |||||||||||||||
prevalence: 12
| |||||||||||||||
Property / knows about: Influenza Virus Research and Epidemiology / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Diagnosis and Management of Fungal Infections / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Diagnosis and Management of Fungal Infections / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Diagnosis and Management of Fungal Infections / qualifier | |||||||||||||||
prevalence: 11
| |||||||||||||||
Property / knows about: Diagnosis and Management of Fungal Infections / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Systemic Lupus Erythematosus and Antiphospholipid Syndrome / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Systemic Lupus Erythematosus and Antiphospholipid Syndrome / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Systemic Lupus Erythematosus and Antiphospholipid Syndrome / qualifier | |||||||||||||||
prevalence: 11
| |||||||||||||||
Property / knows about: Systemic Lupus Erythematosus and Antiphospholipid Syndrome / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Gastrointestinal Viral Infections and Vaccines Development / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Gastrointestinal Viral Infections and Vaccines Development / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Gastrointestinal Viral Infections and Vaccines Development / qualifier | |||||||||||||||
prevalence: 11
| |||||||||||||||
Property / knows about: Gastrointestinal Viral Infections and Vaccines Development / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Coronavirus Disease 2019 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Coronavirus Disease 2019 / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Coronavirus Disease 2019 / qualifier | |||||||||||||||
prevalence: 10
| |||||||||||||||
Property / knows about: Coronavirus Disease 2019 / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Regulatory T Cell Development and Function / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Regulatory T Cell Development and Function / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Regulatory T Cell Development and Function / qualifier | |||||||||||||||
prevalence: 10
| |||||||||||||||
Property / knows about: Regulatory T Cell Development and Function / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Epidemiology and Management of Fungal Infections / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Epidemiology and Management of Fungal Infections / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / knows about: Epidemiology and Management of Fungal Infections / qualifier | |||||||||||||||
prevalence: 9
| |||||||||||||||
Property / knows about: Epidemiology and Management of Fungal Infections / reference | |||||||||||||||
Property / OpenAlex ID | |||||||||||||||
Property / OpenAlex ID: A5061167455 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / OpenAlex ID: A5061167455 / qualifier | |||||||||||||||
last update: 27 August 2024
| |||||||||||||||
Property / OpenAlex ID: A5061167455 / qualifier | |||||||||||||||
retrieved: 29 August 2024
| |||||||||||||||
Property / employer | |||||||||||||||
Property / employer: Fred Hutch Cancer Center / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / employer: Fred Hutch Cancer Center / qualifier | |||||||||||||||
point in time: 2024
| |||||||||||||||
Property / employer: Fred Hutch Cancer Center / reference | |||||||||||||||
Property / same as | |||||||||||||||
Property / same as: http://www.wikidata.org/entity/Q6503944 / rank | |||||||||||||||
Normal rank |
Latest revision as of 16:14, 4 October 2024
USGS collaborator/co-author with Fred Hutchinson Cancer Research Center
Language | Label | Description | Also known as |
---|---|---|---|
English | Lawrence Corey |
USGS collaborator/co-author with Fred Hutchinson Cancer Research Center |
Statements
27 August 2024
102
1 reference
27 August 2024
101
1 reference
27 August 2024
75
1 reference
27 August 2024
34
1 reference
27 August 2024
32
1 reference
27 August 2024
31
1 reference
27 August 2024
30
1 reference
27 August 2024
30
1 reference
27 August 2024
27
1 reference
27 August 2024
27
1 reference
27 August 2024
24
1 reference
27 August 2024
23
1 reference
27 August 2024
20
1 reference
27 August 2024
19
1 reference
27 August 2024
18
1 reference
27 August 2024
17
1 reference
27 August 2024
14
1 reference
27 August 2024
12
1 reference
27 August 2024
12
1 reference
27 August 2024
11
1 reference
27 August 2024
11
1 reference
27 August 2024
11
1 reference
27 August 2024
10
1 reference
27 August 2024
10
1 reference
27 August 2024
1 reference